UNIQURE
LIVE

Serial Number

85907857

Owner

UNIQURE IP B.V.

Attorney

Julianne Abelman

Filing Date

Apr 18, 2013

Add to watchlist:

No watchlists yet
View on USPTO

UNIQURE Trademark

Serial Number: 85907857 • Registration: 4710280

UNIQURE is a trademark filed by UNIQURE IP B.V. on April 18, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

UNIQURE IP B.V. (20 trademarks)

MEIBERGDREEF 61
AMSTERDAM 1105BA , NL

Entity Type: 99

uniQure biopharma B.V. (17 trademarks)

Paasheuvelweg 25
Amsterdam 1105BP , NL

Entity Type: 26

Trademark Details

Filing Date

April 18, 2013

Registration Date

March 31, 2015

Published for Opposition

September 2, 2014

Goods & Services

Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers]

[Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes]

Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disorders

Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 11, 2025 ASGN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 4, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 4, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 4, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 4, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 4, 2025 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jan 27, 2025 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jan 27, 2025 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jan 27, 2025 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 27, 2025 APRE
TEAS SECTION 8 & 9 RECEIVED
Oct 4, 2024 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Mar 31, 2024 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 1, 2021 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 1, 2021 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 10, 2020 APRE
TEAS SECTION 8 & 15 RECEIVED
Sep 17, 2020 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 31, 2020 REM1
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2015 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Nov 18, 2014 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 18, 2014 AITU
NOTICE OF ALLOWANCE CANCELLED
Oct 29, 2014 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Oct 29, 2014 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 28, 2014 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 2, 2014 NPUB
PUBLISHED FOR OPPOSITION
Sep 2, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 28, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 28, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 24, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 24, 2014 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 22, 2014 GNFN
FINAL REFUSAL E-MAILED
Feb 22, 2014 GNFR
FINAL REFUSAL WRITTEN
Feb 22, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2014 CRFA
ASSIGNED TO LIE
Jan 26, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 16, 2014 TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 16, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 5, 2013 GNRN
NON-FINAL ACTION E-MAILED
Aug 5, 2013 GNRT
NON-FINAL ACTION WRITTEN
Aug 5, 2013 CNRT
ASSIGNED TO EXAMINER
Aug 5, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 25, 2013 NWOS
NEW APPLICATION ENTERED
Apr 22, 2013 NWAP